Abstracts tagged "inflammation and systemic sclerosis"

Abstract Number: 812 • 2018 ACR/ARHP Annual Meeting
Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide
Aleksey Mitev¹, Daria Feldmann¹, Moritz Binder², Kim Möller³, Anna-Maria Kanne¹, Thomas Hügle⁴, Peter M. Villiger⁵, Reinhard Voll⁶, Stephanie Finzel¹ and Florian Kollert⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ²Department of Internal Medicine, Mayo Clinic, Rochester, MN, ³Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Rheumatology, University Hospital Lausanne (CHUV), Lausanne, Switzerland, ⁵Rheumatology and Clin Immunol, Bern, Switzerland, ⁶Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁷Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland
Background/Purpose: Elevated levels of C-reactive protein (CRP) in systemic sclerosis (SSc) have been linked to early inflammatory stages of the disease. This study has been…
Abstract Number: 1707 • 2017 ACR/ARHP Annual Meeting
Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
Viktor Martyanov¹, Yolanda Nesbeth², Guoshuai Cai¹, Tammara A. Wood¹, Jake Reder², Scott Constantine³, Barbara White³, Robert F. Spiera⁴ and Michael L. Whitfield¹, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Celdara Medical, LLC, Lebanon, NH, ³Corbus Pharmaceuticals, Inc., Norwood, MA, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Anabasum (JBT-101) is a non-immunosuppressive, synthetic, CB2 agonist that resolves inflammation and fibrosis in animal models of SSc and reduces TGF-β and collagen production…
Abstract Number: 841 • 2016 ACR/ARHP Annual Meeting
Low Nucleoside Triphosphate Pyrophosphohydrolase Activity Contributes to Pathologic Mineralization in Systemic Sclerosis
Yue Ding¹, Supraja Yeturi¹, Claudia Gohr¹, Mary Ellen Csuka¹ and Ann K. Rosenthal^2,3, ¹Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Medicine, Clement J. Zablocki VA Medical Center, Milwaukee, WI
Background/Purpose: Calcinosis is a major source of morbidity in patients with systemic sclerosis (SS). In addition, increased coronary calcification has been reported in patients with…
Abstract Number: 749 • 2014 ACR/ARHP Annual Meeting
Progranulin Overproduction Due to Fli1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor a in Systemic Sclerosis
Yohei Ichimura, Yoshihide Asano, Kaname Akamata, Shinji Noda, Takashi Taniguchi, Takehiro Takahashi, Tetsuo Toyama, Yayoi Tada, Makoto Sugaya, Shinichi Sato and Takafumi Kadono, Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a multisystem fibrotic connective tissue disease characterized by a dysregulated activation of fibroblasts following inflammation, autoimmune attacks, and vascular injuries.…
Abstract Number: 2300 • 2012 ACR/ARHP Annual Meeting
The Effects of Salvianolic Acid B in Fibrotic Models in Vivo and in Vitro
Qingmei Liu¹, Wenyu Wu², Wenzheng Tu³, Haiyan Chu¹, Yanyun Ma¹, Hejian Zou⁴, Xiaodong Zhou⁵ and Jiu-Cun Wang¹, ¹Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China, ²Huashan Hospital, Shanghai, China, ³Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai, China, ⁴Rheumatology, Huashan Hospital, Shanghai, China, ⁵Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: , Methods: , Results: and Conclusion: Background: Scleroderma or systemic sclerosis (SSc) is characterized by the fibrosis of skin and visceral organs. Salvianolic acid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].